Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes
Start Date
9/15/2018
Completion Date
12/30/2026
Summary
The objective of this study is to better understand the comprehensive integration of both clinical and genetic factors that will help to identify mothers who could be at an increased risk of poor response to opioid substitution and infants at risk of significant neonatal abstinence syndrome (NAS).
Detailed Description
One of the greatest impacts on maternal/infant health in the United States today is mother's who have opioid use disorder also known as OUD. This study will look at how in-utero buprenorphine also known as subutex, effects both mother/fetus in prenatal stages with MRI's, blood draws, and a series of assessments. After the neonate is born, there will be follow-up with that baby for up to 2 years with another neonatal MRI, blood draws and infant/child assessments. Planning to enroll 200 mothers who have opioid use disorder and 100 mothers with no previous opioid use.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Subutex / Buprenorphine
Fetal & Neonatal MRI
DNA/Genetic/Pharmacokenetic Blood Draws
Conditions
Locations
UPMC Children's Hospital
Pittsburgh, Pennsylvania 15224
United States